Pan Xue, Shi Minhua
Department of Respiratory and Critical Care Medicine, The Second Affiliated Hospital of Soochow University, Suzhou, 215004, China.
Heliyon. 2024 Feb 24;10(5):e27106. doi: 10.1016/j.heliyon.2024.e27106. eCollection 2024 Mar 15.
Somatic mutations in epidermal growth factor receptor () genes, such as G719X and S768I, and tyrosine kinase inhibitors (TKIs) have been confirmed to be promising for developing new targeted therapies against advanced non-small-cell lung cancer (NSCLC). The G719X and S768I mutations are uncommon and often occur in the form of compound mutations. However, the efficacy of furmonertinib in patients with these uncommon compound mutations has not yet been elucidated.
In this study, the G719X/S768I compound mutations were detected in a critically ill NSCLC patient. This patient received furmonertinib for 14 months and successfully responded to the treatment. The present case report highlights the ideal clinical response, with ongoing follow-up.
We report the successful treatment of a critically ill NSCLC patient carrying rare compound G719X and S768I mutations using furmonertinib. To the best of our knowledge, this is the first reported case of a successful furmonertinib treatment of compound G719X and S768I mutations. Furmonertinib, a third-generation -TKI, may be effective in controlling the G719X and S768I compound mutations in NSCLC.
表皮生长因子受体（EGFR）基因的体细胞突变，如G719X和S768I，以及酪氨酸激酶抑制剂（TKIs）已被证实有望用于开发针对晚期非小细胞肺癌（NSCLC）的新型靶向治疗。G719X和S768I突变并不常见，且常以复合突变的形式出现。然而，伏美替尼在这些罕见复合突变患者中的疗效尚未阐明。
在本研究中，一名重症NSCLC患者检测到G719X/S768I复合突变。该患者接受伏美替尼治疗14个月，治疗反应良好。本病例报告突出了理想的临床反应，目前仍在随访中。
我们报告了使用伏美替尼成功治疗一名携带罕见复合G719X和S768I突变的重症NSCLC患者。据我们所知，这是首例伏美替尼成功治疗复合G719X和S768I突变的病例报告。伏美替尼作为第三代EGFR-TKI，可能对控制NSCLC中的G719X和S768I复合突变有效。
